Vaccine developed in Nebraska could signal end to annual flu shot
Eric Weaver, director of the Nebraska Center for Virology, consults with Zahidul Islam, who recently joined the Weaver laboratory as a graduate student. Weaver led a study whose newly published findings reveal a breakthrough on flu vaccines for swine, birds and humans. (Courtesy of the University of Nebraska-Lincoln)
LINCOLN — A new vaccine strategy developed and tested by a team from the University of Nebraska-Lincoln could signal an end to the annual flu shot routine.
The possible breakthrough is laid out in newly published research in Nature Communications. The study, 'Epitope-Optimized Vaccine Elicits Cross-Species Immunity Against Influenza A Virus,' describes a vaccine that protects against H1N1 swine flu and can also protect against influenza in birds and humans.
'This research sets the stage for developing universal influenza vaccines so people won't have to go to the doctor and get a flu shot every year,' said Eric Weaver, director of the Nebraska Center for Virology who led the Nebraska research team. 'This vaccine will protect you against the different strains that are out there.'
According to a UNL news release, swine vaccinated with immunogens designed in Weaver's lab showed no signs of illness after being exposed to a commonly circulating flu strain. They developed antibodies against multiple viruses from several decades and several species and maintained their immune response throughout the six-month study.
Based on the study results, Weaver said that immunity in pigs could last at least a decade. 'We hope that would translate into humans,' he said.
Called the Epigraph vaccine, after computer software used to design it, the vaccine significantly outperformed a commercial vaccine used by the pork industry and a 'wild type' vaccine based on naturally occurring strains with similar immunogens.
Both the National Institutes of Health and the U.S. Department of Agriculture's National Institute of Food and Agriculture supported the study.
The newly published findings confirm previous research that showed the vaccine design protected against the H3 influenza subtype. Weaver said the new results are particularly encouraging because H1 swine flu variants are detected twice as often as H3 variants and have nearly three times more genetic diversity.
'This H1 subtype is the largest and most genetically diverse subtype in pigs,' Weaver said. 'It's also among the viruses that jumped from swine to humans to cause the 2009 swine flu pandemic. It's a big target and one of the harder targets to hit.'
The UNL team noted that influenza A infects as much as 15% of the human population and causes thousands of deaths annually. Today's vaccines often lack long-lasting protection because of the genetic diversity and rapid mutation of proteins that help form the virus.
Another challenge in controlling influenza, according to UNL, is that it infects multiple species, including birds, swine, horses and dogs, along with humans. 'Swine often act as a mixing vessel because they are susceptible to human and bird flu variants, contributing to the evolution of novel forms of the disease that can be transmitted back to humans,' the statement said.
UNL offered as an example the 2009 swine flu pandemic, transmitted from hogs to humans. About 25% of the human population was infected with the new variant, and more than a half million people died from it in the first year, according to some estimates.
'If we can prevent influenza in swine, we can also prevent zoonotic jumps from avians through swine to humans, or from swine directly to humans,' Weaver said. 'We could basically cut off this evolutionary arsenal or advantage that the virus has.'
A goal, he said, is to produce a pediatric vaccine that will protect people throughout most of their life — and, ultimately, eradicate influenza.
Weaver's vaccine strategy, which has been patented, used the Epigraph software to study genetic codes of more than 6,000 strains of influenza virus from 1930 to 2021 and create a vaccine that represents their most common epitopes.
Epitopes were described as regions on a virus that trigger the immune system to produce antibodies to neutralize the virus and to send T-cells to destroy infected cells. Also according to the news release, some epitopes disappear as the virus evolves. The computer-derived Epigraph strategy increases the likelihood that the vaccine contains the epitopes needed to trigger an immune response and prevent illness.
'Our ability to understand how viruses evolve has increased exponentially in the past 20 years,' Weaver said. 'What I see on the horizon is a third wave, where we go from good vaccines to universal, lifelong vaccines.'
The UNL team now plans to test a vaccine to protect against both H1 and H3 strains of influenza.
Weaver said that he doesn't have a projection yet for when the longer-lasting vaccine for humans might be available, but said his team is in discussions with a biotechnology company for that purpose.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
3 days ago
- Business Upturn
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]
Yahoo
3 days ago
- Yahoo
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX DiagnosticsChris Holeenquires@ Scius CommunicationsKatja Stout+44 778 943 5990katja@ Daniel Gooch+44 774 787 5479daniel@ _____________________1 This LEX Diagnostics product is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available for sale or distribution in the U.S., the U.K. or any other jurisdiction. All product descriptions, data, or discussions are preliminary, subject to change, and do not represent final or FDA-approved claims, indications, or labeling.
Yahoo
5 days ago
- Yahoo
Brandon Weaver and Dr. Grant Williams receive Carthage alumni awards
CARTHAGE, Mo. — Two Carthage alumni are being honored for their actions in the world post-graduation. Officials with Carthage R-9 School District say the Distinguished Tiger Alumni Award Board have announced the inaugural recipients of their Distinguished Tiger Alumni Board, established in honor of Ms. Caroline Tubbs, a lifelong education advocate. The award was created to recognize Carthage High School graduates who have made outstanding contributions in their fields and communities. 2025 Distinguished Tiger Alumni Honorees Brandon Weaver – Class of 2009 Carthage officials say Brandon Weaver of Carthage's Class of 2009 has become a leader in the tech world and is described as a quiet force for good. Weaver currently serves as a Senior Software Engineer at Amazon One Medical. Past career roles have included working for Square, Gusto, Sony PlayStation, and Cerner. Weaver is also said to be a featured speaker in the Ruby programming community, giving presentations all over the world in places like Japan and Brazil. Weaver is known to be a passionate autism awareness advocate and has been a generous supporter of education and athletics; funding classroom wish lists and cross-country programs. Dr. Grant Williams – Class of 2001 Carthage officials say Dr. Grant Williams is a world-renowned oncologist, specializing in geriatric care. He is certified in internal medicine, oncology, and geriatric medicine. Dr. Williams currently serves as a professor and clinical researcher at the University of Alabama Birmingham. Dr. Williams has authored over 200 peer-reviewed scientific publications. Honors include the Exceptional Care Provider Award, Teaching Excellence Award, and Patient Excellence Award. Dr. Williams is known for his work in advancing care and dignity for older cancer patients. Dr. Williams' words for the students of today: 'Work hard and enjoy the journey.' Carthage officials say the two men will be honored at the Carthage High School football game on October 17, 2025.. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.